nuvalore brings GMP rigor to Antibody Drug Conjugate analysis

Leimen, Germany – GMP-certified specialist pharma and biotech analytical characterization laboratory, nuvalore GmbH supports the development of Antibody Drug Conjugates (ADCs) from preclinical and clinical stages through to commercialization, with a strong focus on robust analytical control strategies.

ADCs combine the molecular complexity of biologics with the risk profile of highly potent small-molecule payloads. Their clinical success depends not only on the design of antibody, linker, and payload, but on robust, phase-appropriate analytical control capable of defining and maintaining the critical quality attributes (CQAs) that drive safety, efficacy, and comparability.

De-risking ADC development with phase-appropriate analytics

As ADC programs progress from early development into validation, stability, and clinical manufacturing, analytical requirements become significantly more demanding. Analytical strategies must evolve accordingly — addressing not only molecular characterization, but also ensuring that methods remain reliable and interpretable under GMP conditions and across process changes.

In practice, this requires analytical approaches that are directly linked to patient safety and product performance, and aligned with release, stability, and impurity control strategies appropriate to each development stage.

At nuvalore, analytics are designed and executed within a GMP-certified pharmaceutical quality control environment, ensuring that results are suitable for validation, transfer, and comparability in alignment with ICH guidelines and EU GMP expectations.

GMP-aligned analytical control strategies

The nuvalore analytical approach is based on GMP-aligned analytical control strategies built around the CQAs that define ADC performance and consistency. These attributes directly impact clinical and regulatory outcomes and must be assessed using orthogonal analytical methods to ensure robust and defensible characterization.

Key analytical areas include:

• Drug-to-antibody ratio (DAR) – average and distribution (HIC-HPLC):
  Primary control of conjugation consistency and a key determinant of the efficacy–toxicity balance.
• Size variants and purity (SEC-HPLC, CE-SDS reduced/non-reduced):
  Critical safety-related attributes influencing pharmacokinetics and immunogenicity risk, routinely monitored for release and stability.
• Charge variants (icIEF, CEX):
  Sensitive indicators of conjugation- and process-induced heterogeneity, supporting process consistency and comparability assessments.
• Identity and primary structure (peptide mapping):
  Verification of molecular integrity and monitoring of post-translational modifications to support stability and informed comparability decisions.
• Free cytotoxic payload and related impurities:
  Directly linked to systemic toxicity risk and critical for release and stability control.
• Compendial parenteral testing:
  Ensuring batch release and stability readiness for investigational and commercial injectable drug products.

Enabling confident development decisions

As ADC pipelines continue to expand and evolve, analytical rigor becomes increasingly central to successful development. In this context, analytics are not a supporting activity, but a critical enabler of development decisions, validation success, and regulatory confidence.

By combining phase-appropriate analytical design with GMP execution and orthogonal characterization strategies, nuvalore supports pharmaceutical and biotechnology companies in advancing ADC programs with confidence across development, transfer, and commercialization.

About nuvalore GmbH

nuvalore GmbH is a GMP-certified contract quality control laboratory based in Leimen, Baden-Württemberg, specializing in the analytical characterization of pharmaceuticals and biopharmaceuticals.

Founded in 2024, nuvalore supports clients with analytical method development, validation, and transfer, as well as Quality by Design (QbD)-driven approaches using Design of Experiments (DoE). Its capabilities include pharmacopoeial quality control, protein and surfactant analysis, ELISA, nanoparticle characterization, and testing of primary packaging and drug delivery systems.

Operating under a quality management system aligned with EU GMP and ICH guidelines, nuvalore provides pharmaceutical and biotechnology companies with reliable, regulatory-ready analytical data.

To learn more, visit:  https://nuvalore.com/en/

Resources

Schedule a discussion to exchange ADC perspectives and explore analytical strategies.
Learn more about the nuvalore Quality by Design approach.